U.S. Markets closed
  • S&P 500

    4,026.12
    -1.14 (-0.03%)
     
  • Dow 30

    34,347.03
    +152.97 (+0.45%)
     
  • Nasdaq

    11,226.36
    -58.96 (-0.52%)
     
  • Russell 2000

    1,869.19
    +5.67 (+0.30%)
     
  • Crude Oil

    76.28
    -1.66 (-2.13%)
     
  • Gold

    1,754.00
    +8.40 (+0.48%)
     
  • Silver

    21.43
    +0.06 (+0.29%)
     
  • EUR/USD

    1.0405
    -0.0008 (-0.0728%)
     
  • 10-Yr Bond

    3.6910
    -0.0150 (-0.40%)
     
  • Vix

    20.50
    +0.08 (+0.39%)
     
  • GBP/USD

    1.2091
    -0.0023 (-0.1935%)
     
  • USD/JPY

    139.1000
    +0.5100 (+0.3680%)
     
  • BTC-USD

    16,560.19
    -81.60 (-0.49%)
     
  • CMC Crypto 200

    386.97
    +4.32 (+1.13%)
     
  • FTSE 100

    7,486.67
    +20.07 (+0.27%)
     
  • Nikkei 225

    28,283.03
    -100.06 (-0.35%)
     

Aquestive's AQST-109 Compares Favorably To Widely Used EpiPen For Severe Allergic Reaction

  • Aquestive Therapeutics Inc (NASDAQ: AQST) announced positive topline results from the EPIPHAST 2 trial for its AQST-109 epinephrine sublingual film.

  • The trial was designed to compare single doses of AQST-109 to EpiPen 0.3mg and epinephrine 0.3mg intramuscular (IM) injection and repeat doses of AQST-109 to repeat doses of epinephrine 0.3mg IM injection.

  • EpiPen auto-injectors are used for allergic emergencies.

  • Related: Aquestive Therapeutics Reveals Favorable Data From Epinephrine Trial For Allergies.

  • Single dose administration showed AQST-109 achieved a significantly faster Tmax (12 minutes) compared to both EpiPen (22.5 minutes) and epinephrine 0.3mg IM injection (45 minutes).

  • AQST-109 repeat dosing provided significantly higher drug plasma concentrations, with a Tmax of 8 minutes after administration, and extensive absorption was observed.

  • After one dose of AQST-109, maximum mean effects on systolic blood pressure occurred within 5 minutes of dosing compared to 8 minutes for EpiPen. Maximum mean effects in heart rate occurred within 8 minutes of administering AQST-109 compared to an average of 5 minutes within administering EpiPen.

  • Safety results for AQST-109 were in line with expectations, and no severe or serious adverse events were reported.

  • End-of-Phase 2 meeting with FDA is scheduled for the fourth quarter of 2022, and the remaining clinical studies will commence after that.

  • Price Action: AQST shares are up 8.88% at $1.21 during the market session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.